5-Hydroxy Ivabradine
 
		Product Description
CAT No.
				
									ALN-I014055								
				CAS No.
				
									2253977-80-7								
				Mol. F.
				
									C27H36N2O6								
				Mol. Wt.
				
									484.6								
				Stock
				
									Please Inquire								
				
										
							
										Product Overview
						
											
										
							
										Technical Data
						
											
										
							
										Reference
						
											
										
							
										RFQ
						
									
							
							
							Product Overview
			
						
									Chemical Name : 3-(3-((((S)-3,4-Dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl)methyl)(methyl)amino)propyl)-5-hydroxy-7,8-dimethoxy-1,3,4,5-tetrahydro-2H-benzo[d]azepin-2-one								
				
									Smiles : COC1=C(OC)C=C([C@@H](CN(C)CCCN2CC(O)C3=CC(OC)=C(OC)C=C3CC2=O)C4)C4=C1								
				
									Inchi : InChI=1S/C27H36N2O6/c1-28(16-19-11-18-13-23(33-3)24(34-4)14-20(18)19)8-6-9-29-10-7-17-12-22(32-2)25(35-5)15-21(17)26(30)27(29)31/h12-15,19,26,30H,6-11,16H2,1-5H3/t19-,26?/m1/s1								
				
							
							
							Technical Data
			
						
							
							
							Reference
			
						Forced Degradation Studies of Ivabradine and In Silico Toxicology Predictions for Its New Designated Impurities
									Piotr Pikul,1 Marzena Jamru00f3giewicz,1,* Joanna Nowakowska,1 Weronika Hewelt-Belka,2,3 and Krzesimir CiuranFront Pharmacol. 2016; 7: 117.								
				Simultaneous determination of chiral and achiral impurities of ivabradine on a cellulose tris(3-chloro-4-methylphenylcarbamate) chiral column using polar organic mode
									 Joanna Nowakowska,1 Weronika Hewelt-Belka,2,3 and Krzesimir Ciura – Front Pharmacol. 2016; 7: 117. 								
				Characterization of degradation products of Ivabradine by LC-HR-MS/MS: a typical case of exhibition of different degradation behaviour in HCl and H2SO4 acid hydrolysis
									ElekFerenczabBélaKovácsabFranciscBodaaMohammadhassanForoughbakhshfasaeicÉva KatalinKelemenbGerg?TóthcZoltán-IstvánSzabó – Journal of Pharmaceutical and Biomedical Analysis Volume 177, 5 January 2020, 112851 								
				
							
							
							RFQ
			
						
 
                             
                             
                             
                             
                            